Every year we look back in amazement at everything our partners in universities, research institutes and hospitals have achieved – partly with our help, and often at an astonishing pace. We are witnessing rapid technological advances and numerous start-ups working at many levels to improve healthcare worldwide, especially in the field of digital health. Here the key figures from a knowledge and technology transfer perspective:
- At the end of 2020, Ascenion managed a portfolio of 25 shareholdings. There were seven new participations, four thereof in the field of digital health, and three successful exits or equity transactions.
- Six companies in Ascenion’s 2020 portfolio have acquired a total of EUR 91.5 million in capital.
- 156 agreements relating to the commercial exploitation of IP were closed between Ascenion’s partners and industry, 36 thereof are revenue-carrying agreements.
- About EUR 4.5 million generated from agreements supported by Ascenion were directly transferred to Ascenion’s partners, including licences, options and sales of materials.
- About EUR 2.5 million from Ascenion’s revenues were distributed to the LifeScience Foundation, which makes them available to its endowing institutes in the form of research grants.
- 45 translation projects were intensively accompanied, about EUR 7.5 million in funding was acquired for translation.
- 152 invention disclosures were evaluated, 71 patent applications managed.
- 25 long-term partners were supported, including research institutes, universities and university hospitals. 11 thereof are endowing members of the LifeScience Foundation.
Our special thanks go to our partners in science and industry. Together we have been able to preserve our close relationship in this second year of the coronavirus pandemic. For us this is, alongside the figures presented here, an important indicator of our success.